MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
Belfast base will expand regulatory support, boost innovation and deepen engagement
Read More
Author: John Pinching
Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
Responders achieved weight loss and improvements in physical function
Read More
Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
Lead candidate ETD001 delivers significant lung function improvement
Read More
SMC backs first-line metastatic bladder cancer combination after trial results
Enfortumab vedotin and pembrolizumab recommended for NHS Scotland
Read More
Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
Second national grant strengthens company’s expanding global IP estate
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
